Wednesday 28 February 2018

Reuters Health Report: AstraZeneca spins off autoimmune drugs into new biotech company

AstraZeneca spins off autoimmune drugs into new biotech company

LONDON (Reuters) - AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.

Twenty states sue federal government, seeking end to Obamacare

(Reuters) - A coalition of 20 U.S. states sued the federal government on Monday over Obamacare, claiming the law was no longer constitutional after the repeal last year of its requirement that people have health insurance or pay a fine.

Mississippi moves closer to banning abortions after 15 weeks

(Reuters) - Mississippi moved a step closer on Tuesday to passing the United States' most restrictive abortion law when a state Senate committee approved a bill banning most procedures after 15 weeks of gestation.

U.S. to seek reimbursement from opioid makers, distributors

WASHINGTON (Reuters) - The federal government, backing litigation by states and cities, will seek reimbursement from major drug companies and distributors to recover costs it has borne from the opioid epidemic, the U.S. Justice Department said on Tuesday.

Free clinic opens for Yemenis impoverished by war

SANAA (Reuters) - Volunteer doctors are offering free medical services for a week at a clinic in the Yemeni capital Sanaa to treat people impoverished by a war which has killed thousands and wrecked the economy.

Roche says hemophilia drug Hemlibra wins EU approval

ZURICH (Reuters) - Swiss group Roche said on Tuesday the European Commission has approved its drug Hemlibra for people with hemophilia A who have developed resistance to standard treatments.

Many mothers may lack knowledge about child burn risk, treatment

(Reuters Health) - Mothers of young children may be largely unaware of the biggest burn risks to their little ones and even what age group is most likely to get burned, Australian researchers say.

U.S. FDA rejects filing for Celgene MS drug, shares fall

(Reuters) - U.S. health regulators have rejected Celgene Corp's application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said on Tuesday, a surprise development that will likely delay the entry to market of one of Celgene's most important pipeline assets.

Teen sexting may be more common than you think

(Reuters Health) - At least one in four teens are receiving sexually explicit texts and emails, and at least one in seven are sending sexts, a new study suggests.

Aerobic exercise slows cognitive decline in Alzheimer's disease

(Reuters Health) - Cardiovascular exercise training may help slow the decline in brain function seen in Alzheimer's patients, a new review of past research suggests.

Related Videos

Hybrid bee at the heart of UAE sustainable honey plan

Technology to help deepen our relationship with wild animals

Read Reuters on the go

Download the free Reuters News app today for breaking news, analysis and market data from the world's most trusted news organization.

Get the app